April 2023 | ISSUE #19

Patient and Family Advisory Council

Cuthbert Lab & Oncology Outcomes

Welcome

Oncology Outcomes held its inagural annual retreat this April in Canmore, AB.

We kicked off the retreat with a review of the team's milestones over the last few years, followed by a walkthrough of the equity, diversity, and inclusion (EDI) initiatives we have implemented over the last few months. As a group we re-aligned on our digital presence strategy and discussed the areas of improvement for our current O2 website. A few of our team members presented on their ongoing research and received some wonderful feedback from the wider team. In our last session, we put our heads together to brainstorm ideas for future grants, projects, and initiatives.

Overall, we were able to re-connect and recalibrate as a team. Having Canmore, Alberta as the backdrop for our retreat only strengthened our "can-more, can-do-more" attitude!





Research Highlights

Oncology Outcomes

The impact of population-based EGFR testing in nonsquamous metastatic non-small cell lung cancer in Alberta, Canada

BACKGROUND

Tyrosine Kinase Inhibitors (TKI) are a class of agents widely used to treat non-small cell

lung cancer (NSCLC)



Few studies have evaluated the impact of the implementation of molecular diagnostics and testing at the population-level To ensure that results observed in phase III clinical trials are mirrored in the real world, molecular testing and targeted therapies must be evaluated at the population-level

STUDY GOAL: Examine the impact of population-level EGFR testing and treatment on survival outcomes among non-squamous metastatic NSCLC patients in Alberta, Canada from 2004-2020

METHODS

Patients aged 18+ with a de novo diagnosis of stage IV (metastatic) non-small cell lung cancer (NSCLC) and a confirmed non-squamous cell carcinoma histology between Jan 2004 and Dec 2019.

Differences between patient outcomes pre and post initiation of EGFR testing were evaluated

RESULTS

Patients diagnosed in the post-EGFR testing period had significantly greater overall survival than patients diagnosed in the pre-EGFR testing period (HR: 0.81; 95% CI: 0.78-0.85).

6-month, 1-year, and 2-year mortality rates significantly decreased after the initiation of EGFR testing

CONCLUSIONS

Among patients who initiated systemic therapy, patients who were tested for an EGFR mutation had improved outcomes compared to those who were not tested.



Cuthbert Lab

Patient-reported symptom burden and supportive care needs at diagnosis: a retrospective cohort study

BACKGROUND

Cancer patients	The evaluation of	
experience a range of physical and psychological symptoms,	Symptom &	Supportive care needs
	at diagnosis is important to	
as well as supportive	mitigate	improve
care needs at the onset of a cancer diagnosis.	physical psychological morbidity	coping treatment compliance

STUDY GOAL: Evaluate Patient-reportd outcomes (PROs) from the provincial cancer program in Alberta, Canada

METHODS

Retrospective, population-based cohort study using administrative health data of patients in Alberta, Canada, diagnosed with cancer between January 1, 2016, and October 23, 2017.

Adults who completed PROs (Edmonton Symptom Assessment System, ESAS) and supportive care needs inventory (Canadian Problem Checklist)) within ± 60 days of diagnosis were included. Patients were stratified by tumor types.

RESULTS



Comorbidity Index

(CCI) score of ≥ 1

Severity based on ESAS was low for the entire cohort

Prevalence of specific symptoms at diagnosis was high (tiredness, pain, anxiety, low well-being)

Common supportive care needs across tumor groups included:

needing more information about cancer

help communicating with the health care team

CONCLUSIONS

Symptom severity was generally low.



Symptom prevalence for certain symptoms was high.



Symptoms and Supportive care needs at diagnosis differed depending on tumor type.

Click here for full article.

Click here for full article.

Study Recruitment

We continue to actively recruit participants for several studies right now, including:



Healthcare Provider and Patient Views on Prescribing Opioids for Cancer Patients. Poster Link to Share Patients Perspectives of Value Frameworks Used to Guide Oncology Treatment Decisions Poster Link to Share


If you think the studies might be relevant to your contacts, please feel free to share the website or poster links. For the additional details on each study click <u>here</u>.



The next newsletter will release in May 2023.

Previous issues of the PFAC newsletter have been posted online: <u>https://www.cuthbertlab.com/advisory-counci</u>l

Follow us on social media







SAVE THE DATE MAY 13, 2023 BUMRUN CALGARY

On May 13th the annual Bumrun will be held in Calgary. The Bumrun is a 5K walk/run founded by Dr. Ian Bookman to raise awareness for colorectal cancer and encourage early screenings. Since 2011, the Bumrun has raised over \$900,000 for colon cancer research, enhancing patient support programs for families living with colon cancer, and raising awareness of colon cancer screening and prevention.

